TAMPA, Fla.--(BUSINESS WIRE)--Xcelience, a leader in early development services, recognizes that providing access to a third, dedicated Xcelodose® 120S precision powder micro-dosing system in the experimental area enables clients to accelerate drug development with preliminary compound evaluation, earlier go/ no-go decisions and flexible options for experimental studies.
